ArticleVirology journal2025
Hepatitis E virus in immunocompromised children in Argentina: first report from a high-risk group.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHepatitis E virus (HEV) is an emerging zoonosis that can lead to chronic hepatitis in immunocompromised individuals. While HEV genotype 3 circulates in Argentina, data on pediatric populations, especially those immunosuppressed, are scarce. We hypothesized that immunosuppressed children in a region with known zoonotic HEV circulation would show higher seroprevalence compared to healthy controls.
methodsThis pilot descriptive cross-sectional study was conducted at a pediatric referral center in Rosario, Argentina, from 2018 to 2020. Fifty-eight immunocompromised children (aged 8 months-17 years) were enrolled, alongside 101 age-matched healthy controls. Anti-HEV IgG and IgM antibodies were detected by ELISA; HEV RNA was assessed by RT-qPCR. Statistical analyses included chi-square and logistic regression tests.
resultsAnti-HEV IgG was detected in 6.9% (4/58) of immunosuppressed patients, whereas no seropositivity was observed among controls (0/101; p = 0.0075). No cases of active or recent infection (IgM or RNA positive) were found. Anti-HEV IgG prevalence was highest among adolescents (10.0%) and patients with autoimmune diseases (28.6%), though subgroup comparisons lacked statistical significance. One IgG-positive patient had prior intravenous immunoglobulin exposure, suggesting possible passive antibody transfer.
conclusionsThis study provides the first evidence of HEV exposure in immunosuppressed pediatric patients in Argentina, revealing a significantly higher seroprevalence compared to healthy peers. Although no active infections were detected, findings support the need for targeted HEV surveillance in high-risk pediatric groups, particularly in regions with confirmed zoonotic HEV circulation. Future multicenter, longitudinal studies are warranted to evaluate clinical outcomes and guide prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.